OSTRAVSKA UNIVERZITA

Their core work

Ostrava University is a Czech public university based in the Moravian-Silesian region that contributes specialist research capacity to large international EU consortia. Their H2020 participation spans two unrelated fields: algal microbiome science — studying the microbial communities (pathogens, symbionts, endophytes, and biofilm-forming microorganisms) that colonize seaweeds and microalgae — and clinical research into off-patent medicine for neonatal brain injury. In their most substantive project (ALFF), they contributed to fundamental research with direct implications for algal aquaculture productivity and biotechnology applications. Their role in the clinical trial ALBINO, given the negligible EUR 396 in funding received, almost certainly reflects participation as a hospital site or patient data provider rather than as a research driver.

What they specialise in

How they've shifted over time

In their early H2020 phase (2015–2018), Ostrava University focused exclusively on algal biology — specifically the microbial ecology of seaweeds and microalgae, with relevance to aquaculture and environmental science. Their subsequent participation shifted entirely to health and medicine, specifically the clinical evaluation of off-patent drugs for neonatal brain injury treatment. These two domains are largely unrelated, which suggests the EU activity reflects different faculties or research groups within the same broad institution rather than any coherent strategic evolution in research focus.

With only two projects in unrelated fields, there is no reliable institutional trend signal — future collaboration would need to target a specific department or research group rather than the university as a whole.

How they like to work

Ostrava University has participated exclusively as a consortium partner and has never coordinated an H2020 project. Despite only two projects, they have connected with 44 unique partners across 18 countries, which reflects participation in large, internationally-structured consortia rather than small bilateral collaborations. This pattern indicates comfort operating within complex multi-partner projects, though always in a supporting rather than a leadership role.

Their 44 consortium partners across 18 countries — generated from just two projects — indicate involvement in large pan-European consortia, with broad but likely shallow connections to institutions across Central and Western Europe.

What sets them apart

Ostrava University is a mid-sized Czech regional university whose international research network is disproportionately large relative to its EU project count. Their value to consortium builders lies in specialist contributions from specific research groups — most credibly in algal microbiology and aquaculture biology — rather than in institutional leadership or infrastructure. Any prospective partner should reach out to specific faculties directly, as the university's H2020 record spans two wholly unrelated scientific domains.

Highlights from their portfolio

• ALFF
  Their most substantive H2020 contribution (EUR 232,422 received), addressing the relatively niche field of algal microbiome science with direct implications for sustainable aquaculture and algal biotechnology.
• ALBINO
  A long-running pan-European clinical trial (2016–2025) testing an off-patent drug for neonatal brain injury, though OU's EUR 396 allocation strongly suggests a minor clinical data-site role.